TAS::75 0849::TAS

洛杉矶SEER残留组织库（RTR）将为研究目的提供基于组织的资源，包括来自HIV/AIDS患者的癌症肿瘤标本和来自多肿瘤块中无HIV/AIDS患者的类似癌症肿瘤标本。艾滋病毒/艾滋病患者将从以前的洛杉矶县卫生服务部艾滋病毒/艾滋病南加州大学癌症监测计划数据库链接中确定，也将从今年提出的新链接中确定。其目的是开发一个生物标本收集970癌症患者。以下类型的癌症标本将用于HIV/AIDS病例：黑色素瘤（n = 30）、霍奇金淋巴瘤（n=30）、非霍奇金淋巴瘤（n=200）、肺癌（n=50）、宫颈癌（n=40）和肛门癌（n=40）。未受HIV/AIDS影响但患有类似癌症的癌症患者也将被选择用于与2：1匹配比进行比较，但非霍奇金淋巴瘤癌症也将被选择用于与1：1匹配比进行比较。尽可能从洛杉矶SEER残留组织储存库获取标本（第1阶段）。在获得患者同意后，将直接从医院获得额外的标本（第2阶段）。将制备含有肿瘤标本核心或样本的多肿瘤和/或组织微阵列，并将其与去识别SEER数据相关联（III期）。这项研究资源将提供给NCI作为研究资源，以研究HIV/AIDS阳性和阴性癌症患者之间肿瘤标志物谱的差异。国家癌症研究所艾滋病组织资源将成为已完成资源的记录之家。出于保密目的，洛杉矶SEER登记中心将保存将标本编号与标识符联系起来的文件。一个包括洛杉矶SEER RTR和NCI人员在内的顾问委员会将共同审查使用由此产生的生物标本收集的申请。

The Los Angeles SEER Residual Tissue Repository (RTR) will produce a tissue-based resource for research purposes consisting of cancer tumor specimens from HIV/AIDS patients and similar cancer tumor specimens from patients without HIV/AIDS in a multi-tumor block. HIV/AIDS patients will be identified from the previous Los Angeles County Department of Health Services HIV/AIDS ¿USC Cancer Surveillance Program database linkage, and also from a new linkage proposed for this coming year. The objective is to develop a collection of biospecimens 970 cancer patients. The following types of cancers specimens will be targeted for cases with HIV/AIDS: melanoma (n-30), Hodgkin lymphoma (n=30), non-Hodgkin lymphoma (n=200), lung cancer (n=50), cervical cancer (n=40), and anal cancer (n=40). Cancer patients unaffected by HIV/AIDS but with similar cancers will also be selected for comparison with a 2:1 matching ratio with the exception of non-Hodgkin lymphoma cancers will also be selected for comparison with a 1:1 matching ratio,. Specimens will be obtained from the Los Angeles SEER Residual Tissue Repository to the extent possible (Phase 1). Additional specimens will be obtained directly from hospitals after obtaining consent from patients (Phase 2). Multi-tumor and/or tissue microarrays containing cores or samples of the tumor specimen will be prepared and linked to deidentified SEER data (Phase III). This research resource will made available to NCI as a research resource to study differences in tumor marker profiles between HIV/AIDS positive and negative cancer patients. The NCI AIDS Tissue Resource will be the home of record for the completed resource. For confidentiality purposes, the Los Angeles SEER registry will maintain files that link specimen numbers to identifiers. An advisory board that includes Los Angeles SEER RTR and NCI personnel will co-review applications to use the resulting biospecimens collection.